(secondQuint)Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia.

 To assess the bioequivalence of Vidaza(R) and Luitpold Azacitidine pharmacokinetics, in terms of Cmax, AUC0-t and AUC0-, following SC administration.

 To assess the comparative safety of Vidaza(R) versus Luitpold Azacitidine during the 2 day study period.

.

 Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia@highlight

The purpose of this study is to assess the bioequivalence of subcutaneous Vidaza(R) and subcutaneous Luitpold Azacitidine pharmacokinetics and to assess the comparative safety of subcutaneous Vidaza(R) versus subcutaneous Luitpold Azacitidine.

